BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20215039)

  • 1. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
    Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
    Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy.
    Herbert C; Morris WJ; Hamm J; Lapointe V; McKenzie M; Pickles T; Spadinger I; Keyes M
    Brachytherapy; 2011; 10(6):442-8. PubMed ID: 21398190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.
    Munro NP; Al-Qaisieh B; Bownes P; Smith J; Carey B; Bottomley D; Ash D; Henry AM
    Radiother Oncol; 2010 Jul; 96(1):34-7. PubMed ID: 20362348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Schaar S; Borchers H; Heidenreich A; Eble MJ
    Radiother Oncol; 2010 Jul; 96(1):25-9. PubMed ID: 20231039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    Stone NN; Stone MM; Rosenstein BS; Unger P; Stock RG
    J Urol; 2011 Feb; 185(2):495-500. PubMed ID: 21167528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.
    Crook J; Borg J; Evans A; Toi A; Saibishkumar EP; Fung S; Ma C
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1323-9. PubMed ID: 20675072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
    Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
    J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy.
    Hinnen KA; Battermann JJ; van Roermund JG; Moerland MA; Jürgenliemk-Schulz IM; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1433-8. PubMed ID: 19540075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results.
    Genebes C; Filleron T; Graff P; Jonca F; Huyghe E; Thoulouzan M; Soulie M; Malavaud B; Aziza R; Brun T; Delannes M; Bachaud JM
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):651-8. PubMed ID: 24138913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
    Thames HD; Kuban D; Levy LB; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Radiother Oncol; 2010 Jul; 96(1):6-12. PubMed ID: 20400191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
    BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.